QR Kod

Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcome...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wiley 2026-03-01
Seri Bilgileri:Cancer Medicine
Konular:
common EGFR mutation
dacomitinib
epidermal growth factor receptor mutation
non‐small cell lung cancer (NSCLC)
tyrosine kinase inhibitor
Online Erişim:https://doi.org/10.1002/cam4.71659
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller